Levi & Korsinsky Announces Investigation of Securities Claims Against GeneDx Holdings Corp. (WGS)

GeneDx stock collapsed approximately 44% after Q1 2026 earnings revealed a major revenue miss and a roughly 12% cut to full-year guidance -- weeks after management publicly reaffirmed its outlook GeneDx stock collapsed approximately 44% after Q1 2026 earnings revealed a major revenue miss and a roughly 12% cut to full-year guidance -- weeks after management publicly reaffirmed its outlook